美中嘉和(02453.HK)獲控股股東上海醫學之星增持4.56萬股H股
格隆匯5月7日丨美中嘉和(02453.HK)公告,公司控股股東(定義見香港聯合交易所有限公司證券上市規則之一醫學之星(上海)企業管理有限公司知會公司董事會,上海醫學之星於2025年5月7日以每股6.84港元的價格從公開市場購入合共4.56萬股公司H股,總對價爲311,904.00港元,佔截至本公告日期本公司已發行股份總數約0.01%。此舉充分體現上海醫學之星對公司未來前景的信心和對公司持續發展的支持。
據上海醫學之星告知,其對集團的業務前景及增長充滿信心。在符合適用的法律及監管要求的情況下,上海醫學之星不排除會在自本公告日期起6個月內的適當時候通過於公開市場上購買公司額外H股進一步增持公司股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.